Background Aim of this study was to prepare the hyaluronic acid and human serum albumin
modified erlotinib nanoparticles (ERT-HSA-HA NPs) delivery system by a precipitation …

Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related mortality in
China. This study aimed to develop a hyaluronic acid (HA) decorated, pH sensitive lipid …

Purpose Erlotinib (ETB) is a well-established therapeutic for non-small-cell lung cancer
(NSCLC). To overcome drug resistance and severe toxicities in the clinical application …

Core–shell type lipid–polymer hybrid nanoparticles (CSLPHNPs) have emerged as a
multifunctional drug delivery platform. The delivery system combines mechanical …

Erlotinib was loaded on albumin nanoparticles for the first time and the cytotoxic effect of the
resulting nanoparticles against ASPC-1 and PANC-1 pancreatic adenocarcinoma cell lines …

Poor water solubility and low oral bioavailability limit the clinical application of Erlotinib as
an anticancer. For this purpose, we encapsulated erlotinib in the solid lipid nanoparticles …

Non-small cell lung cancer (NSCLC) is a global concern as one of the leading causes of
cancer deaths. The treatment options for NSCLC are limited to systemic chemotherapy …

Targeted delivery of natural bioactive molecules has the potential to reduce toxicity while
increasing anticancer therapeutic efficacy. Nanoparticles (NPs) conjugated with targeting …

Gefitinib, a selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, has
showed remarkable activity in non-small cell lung cancer patients with tumors carrying …

This study was aimed at developing a nanoparticle strategy to overcome acquired
resistance against erlotinib in non-small cell lung cancer (NSCLC). To load erlotinib on …